MD4851C1 - Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi - Google Patents

Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi Download PDF

Info

Publication number
MD4851C1
MD4851C1 MDA20210032A MD20210032A MD4851C1 MD 4851 C1 MD4851 C1 MD 4851C1 MD A20210032 A MDA20210032 A MD A20210032A MD 20210032 A MD20210032 A MD 20210032A MD 4851 C1 MD4851 C1 MD 4851C1
Authority
MD
Moldova
Prior art keywords
compound
pharmaceutically acceptable
steroid
disorder
treatment
Prior art date
Application number
MDA20210032A
Other languages
English (en)
Romanian (ro)
Russian (ru)
Other versions
MD20210032A2 (ro
MD4851B1 (ro
Inventor
Владимир НЕБОЛЬСИН
Original Assignee
Ооо "Валента-Интеллект"
ПУ НЕБОЛЬСИН Владимир Евгеньевич
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Валента-Интеллект", ПУ НЕБОЛЬСИН Владимир Евгеньевич filed Critical Ооо "Валента-Интеллект"
Publication of MD20210032A2 publication Critical patent/MD20210032A2/ro
Publication of MD4851B1 publication Critical patent/MD4851B1/ro
Publication of MD4851C1 publication Critical patent/MD4851C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MDA20210032A 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi MD4851C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Publications (3)

Publication Number Publication Date
MD20210032A2 MD20210032A2 (ro) 2021-09-30
MD4851B1 MD4851B1 (ro) 2023-04-30
MD4851C1 true MD4851C1 (ro) 2023-11-30

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
MDA20210032A MD4851C1 (ro) 2018-11-23 2019-11-22 Utilizarea derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
MDA20210050A MD4844C1 (ro) 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Family Applications After (1)

Application Number Title Priority Date Filing Date
MDA20210050A MD4844C1 (ro) 2018-11-23 2019-11-22 Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi

Country Status (19)

Country Link
US (1) US20220362230A1 (enExample)
EP (2) EP3884945A4 (enExample)
JP (2) JP2022508167A (enExample)
KR (2) KR20220162821A (enExample)
CN (2) CN113164464A (enExample)
AU (2) AU2019384626A1 (enExample)
BR (1) BR112021009801A2 (enExample)
CA (1) CA3120882A1 (enExample)
CL (2) CL2021001316A1 (enExample)
EA (1) EA201992646A1 (enExample)
GE (4) GEAP202215712A (enExample)
IL (2) IL297533A (enExample)
MD (2) MD4851C1 (enExample)
MX (2) MX2021006032A (enExample)
MY (1) MY209416A (enExample)
PH (1) PH12021551152A1 (enExample)
RU (1) RU2712281C1 (enExample)
WO (1) WO2020106191A1 (enExample)
ZA (2) ZA202104247B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
BR112013020498A2 (pt) * 2011-02-10 2016-08-09 Genqual Corp método para determinar a capacidade de resposta a inibidores e para tratamento de um sujeito
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
EP3722290B1 (en) * 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
GEAP202115467A (en) * 2017-09-07 2021-10-11 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

Also Published As

Publication number Publication date
KR20220162821A (ko) 2022-12-08
EP4218758A2 (en) 2023-08-02
PH12021551152A1 (en) 2021-10-25
RU2712281C1 (ru) 2020-01-28
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MX2022013503A (es) 2022-11-16
GEP20237467B (en) 2023-02-10
EA201992646A1 (ru) 2020-05-31
KR20210095652A (ko) 2021-08-02
ZA202210444B (en) 2023-01-25
MD20210032A2 (ro) 2021-09-30
GEAP202415619A (en) 2024-03-11
EP3884945A1 (en) 2021-09-29
CL2022000683A1 (es) 2022-10-28
IL297533A (en) 2022-12-01
BR112021009801A2 (pt) 2022-03-03
IL283317A (en) 2021-07-29
JP2023015333A (ja) 2023-01-31
GEAP202215712A (en) 2022-10-10
GEP20247643B (en) 2024-07-10
MD20210050A2 (ro) 2021-12-31
MY209416A (en) 2025-07-08
ZA202104247B (en) 2023-03-29
AU2022256212B2 (en) 2024-08-15
AU2019384626A1 (en) 2021-07-15
MX2021006032A (es) 2021-07-06
AU2022256212A1 (en) 2022-12-08
CL2021001316A1 (es) 2021-10-29
MD4851B1 (ro) 2023-04-30
CN113164464A (zh) 2021-07-23
EP4218758A3 (en) 2023-08-23
CN114652721A (zh) 2022-06-24
MD4844B1 (ro) 2023-02-28
MD4844C1 (ro) 2023-09-30
WO2020106191A1 (ru) 2020-05-28
US20220362230A1 (en) 2022-11-17
EP3884945A4 (en) 2022-11-23
CA3120882A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
Hanania Targeting airway inflammation in asthma: current and future therapies
AU2014249456B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
US10232018B2 (en) ACTH for treatment of acute respiratory distress syndrome
US20150352101A1 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
JPH02502278A (ja) とくに後天性免疫不全状態の処置のための、免疫調整及び抗ウイルス効果を有する医薬の調製におけるモルヒネ拮抗剤の使用
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
AU2022256212B2 (en) Glutarimide derivative for overcoming resistance to steriods
US20140329782A1 (en) Combined therapeutic agent
JP2020500864A5 (enExample)
WO2010062658A1 (en) Compositions and methods of treating demyelinating central nervous system diseases
JP2005511767A (ja) Ｈｉｖ−１プロテアーゼインヒビターおよびその誘導体の、炎症の処置における使用
EP3167881B1 (en) Locally administered ethamsylate as a medicament
EA046267B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
EA043839B1 (ru) Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
OA20849A (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
OA20833A (en) Use of Glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling.
HK40074427A (en) USE OF GLUTARIMIDE DERIVATIVES FOR OVERCOMING STEROID RESISTANCE AND TREATING DISEASES ASSOCIATED WITH ABERRANT INTERFERON γ SIGNALING
HK40059361A (en) Glutarimide derivative for overcoming resistance to steriods
Zalyhina et al. Hepatoprotective effect of spissum extract from immature walnut based on model of paracetamol-induced acute liver injury in rats
RU2736082C1 (ru) Фармацевтическая композиция противоаллергического и противовоспалительного действия для интраназального применения
JP2001512446A (ja) メラニンによるサイトカインの調整
JPS63101323A (ja) 鎮痛、抗炎症及び抗アレルギ−剤

Legal Events

Date Code Title Description
GB9A Change of applicant (patent for invention)

Owner name: LTD VALENTA-INTELLEKT, RU UL. RYABINOVAYA, D. 26 BUILDING 10, CAB. 6-26, MOSCOW, 121471, FEDERATIA RUSA;IP NEBOLSIN VLADIMIR EVGHENIEVICH, RU STR. GOLITSYNSKAYA, 457, ISTRINSKIY R-N, D. BORZYE, MOSKOVSKAYA OBL., 143581, FEDERATIA RUSA

Free format text: PREVIOUS APPLICANT: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES",RU 121205, MOSCOW, MOZHAISKY MUNICIPAL DISTRICT, TERRITORY OF THE SKOLKOVO INNOVATION CENTER, BOLSHOY BOULEVARD, HOUSE 42, BUILDING 1, FLOOR 3, ROOM 1280, FEDERATIA RUSA

FG4A Patent for invention issued